01—Abstract
Summary
Summary of the 10-Q filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc. reported strong financial performance for the third quarter and first nine months of 2025, with total revenues increasing by 12%a and 11% year-over-year, respectively, driven primarily by robust volume growth across its key products.
Net income saw significant increases, up 14%b for the quarter and a substantial 84% for the nine-month period, leading to a corresponding surge in diluted Earnings Per Share (EPS). The company demonstrated effective cost management, with operating expenses growing at a slower pace than revenues. Strategic investments in late-stage clinical programs continue, supported by strong operational cash flow generation.
The company's balance sheet remains solid, though cash and cash equivalents decreased slightly from year-end 2024, largely due to significant debt repayment and dividend payments. Amgen continues to manage its debt effectively, reducing its overall debt principal.
The company also highlighted ongoing legal matters, particularly the significant U.S. Tax Court case, which, while expected to be resolved no earlier than the second half of 2026, continues to be a point of attention. Despite potential regulatory headwinds and ongoing litigation, Amgen's operational performance and strategic investments indicate a positive outlook for future growth.
02—Key points
Key Highlights
- Total revenues grew by 12% to $9.6 billion for Q3 2025 and 11% to $26.9 billion for the first nine months of 2025.
- Net income surged by 14% to $3.2 billion for Q3 2025 and 84% to $6.4 billion for the nine-month period.
- Diluted EPS increased by 14% to $5.93 for Q3 2025 and 84% to $11.77 for the nine-month period.
- Operating income saw a strong increase of 23% for Q3 2025 to $2.5 billion and 29% for the nine-month period to $6.4 billion.
- Product sales showed robust growth, up 12% to $9.1 billion for Q3 and 11% to $25.8 billion for the nine months, driven by volume.
- Significant investments in R&D increased by 31% for the quarter and 21% for the nine months, reflecting pipeline advancement.
- The company generated $8.4 billion in cash from operating activities for the nine months ended September 30, 2025, a substantial increase from the prior year.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Amgen Inc kept $0.34.
- Revenue$9.56B100.0%
- Cost of revenue−$3.08B32.2%
- Gross profit$6.47B67.8%
- Operating costs−$3.95B41.3%
- Operating income$2.53B26.4%
- Interest, other & tax$690.0M7.2%
- Net income$3.22B33.7%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed November 5, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $9.56B$8.50B | +12.4% |
| Cost of Revenue | $3.08B$3.31B | −6.9% |
| Gross Profit | $6.47B$5.19B | +24.7% |
| SG&A Expenses | $1.72B$1.63B | +5.8% |
| Operating Expenses | $7.03B$6.46B | +8.9% |
| Operating Income | $2.53B$2.05B | +23.4% |
| Interest Expense | $685.00M$776.00M | −11.7% |
| Net Income | $3.22B$2.83B | +13.6% |
| EPS (Basic) | $5.98$5.27 | +13.5% |
| EPS (Diluted) | $5.93$5.22 | +13.6% |
| Shares Outstanding (Basic) | 538.00M537.00M | +0.2% |
| Shares Outstanding (Diluted) | 542.00M542.00M | 0.0% |
05—Questions
Frequently Asked Questions
What were the main drivers of Amgen's revenue growth in Q3 2025?
Amgen's revenue growth in Q3 2025 was primarily driven by a 12% increase in total product sales, reaching $9.1 billion. This growth was fueled by a 14% increase in volume across key products such as PAVBLU, Repatha, EVENITY, IMDELLTRA/IMDYLLTRA, TEZSPIRE, and BLINCYTO, partially offset by a 4% decline in net selling price.
How did operating expenses change, and what is impacting them?
Operating expenses increased by 9% for the quarter, primarily due to investments in late-stage clinical programs and $400 million in Otezla intangible asset impairment charges. For the nine-month period, operating expenses increased by 6%, also influenced by R&D investments and the Otezla impairment, but partially offset by lower amortization expenses related to the Horizon acquisition.
What is the status of Amgen's significant U.S. Tax Court case?
The U.S. Tax Court case, related to IRS proposed adjustments for tax years 2010-2015, had its trial conclude in January 2025. Post-trial briefs were filed in October 2025. A decision from the court is not expected before the second half of 2026. Amgen firmly believes the IRS positions are without merit and is contesting them.
How is Amgen managing its debt and returning capital to shareholders?
Amgen is actively managing its debt, with total debt principal decreasing from $61.8 billion at the end of 2024 to $56.0 billion as of September 30, 2025, through repayments and opportunistic repurchases. The company also continues to return capital to shareholders through quarterly cash dividends, recently increased to $2.38 per share, and has $6.8 billion remaining authorization under its stock repurchase program.
06—Continue